R & D Capabilities
VaxInnate’s R&D capabilities extend from our group of specialty labs staffed with experienced, highly skilled scientists, engineers and associates. We also have relationships with research and development partners such as Princeton University and a variety of contract labs.
Our areas of scientific expertise include:
• Molecular Biology and Protein Science
• Preclinical Immunology
• Manufacturing Process Development
• Analytical Assays and QC Testing
• Clinical Immunology
PreClinical Development and Testing: VaxInnate has fully equipped labs for molecular cloning, bench scale protein purification and preclinical testing. Our preclinical development capabilities range from the rational design of vaccines based on protein structure to the development and execution of models and methods that demonstrate the protective immunity and efficacy of our vaccines.
Process, Analytical and Formulation Development: Our process development lab includes a fully equipped pilot plant, a small-scale purification lab and a testing lab. The pilot plant supports all fermentation, at scale purification, buffer/media prep and in-process assays. The capabilities of this lab cover the development of Phase I manufacturing processes and the oversight of cGMP manufacturing at our CMO partners.
We have fully equipped analytical assay method development and QC labs which support manufacturing process development and cGMP product testing. These labs develop, qualify and execute biophysical and biological assays to measure the quantity, purity and potency of our vaccine candidates throughout process development, cGMP manufacturing and stability testing.
The formulation lab supports pre-process and Phase I formulation development for our vaccine candidates.
Clinical Immunology Lab: Our clinical immunology lab is a fully equipped lab (BSL2) for human serology with ELISA, Biacore and qPCR capabilities. The focus of the lab is the development, qualification and execution of immunological assays to determine the clinical potency of our vaccine candidates.